NCT07391670 2026-03-12
IMFINZI-subQ
AstraZeneca
Phase 1 Not yet recruiting
Clinical Trials
11 trialsNCT07107750 2026-02-04
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT06855225 2026-01-14
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT07122089 2025-08-14
IOSPHERE
Center Eugene Marquis
Phase 2 Not yet recruiting
NCT07012798 2025-06-10
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06274879 2025-01-09
Ablatio
Insel Gruppe AG, University Hospital Bern
Phase 2 Not yet recruiting
NCT06591650 2024-09-19
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06530823 2024-07-31
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Not yet recruiting
NCT06304597 2024-03-12
PREDICT
University Medical Center Groningen
Phase 1 Not yet recruiting
NCT06111326 2023-11-01
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Not yet recruiting